NextCure, Inc. (NXTC) shareholders
Close on Nov 16, 2026Market cap $30.58MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (15.80%) | 722,419 | 15.80% | 13G (passive) | Jul 31, 2026 |
| Ikarian Capital, LLC Joint filing with Neil Shahrestani (9.99%) | 502,672 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| JP Sailing Capital Ltd Joint filing with Jianping Huang (9.90%) | 455,001 | 9.90% | 13G (passive) | Sep 30, 2026 |
| Ren Jinsheng Joint filing with Simcere Zaiming, Inc. (9.40%), Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (9.40%) and 3 more | 338,636 | 9.40% | 13G (passive) amendment | Dec 31, 2025 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (7.67%), Phillip Gross (7.67%) | 277,202 | 7.67% | 13G (passive) | Jun 30, 2026 |
| Michael Cho Joint filing with Affinity Asset Advisors, LLC (6.40%) | 274,073 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Sofinnova Venture Partners IX, L.P. ("SVP IX") Joint filing with Sofinnova Management IX, L.L.C. ("SM IX") (7.10%), Dr. James I. Healy ("Healy") (7.10%) | 222,654 | 7.10% | 13D (active) amendment | Dec 19, 2025 |
| Affinity Asset Advisors, LLC Joint filing with Affinity Healthcare Fund, LP (7.17%) | 191,882 | 7.17% | 13G (passive) amendment | Sep 30, 2025 |
| Devesh Gandhi Joint filing with SilverArc Capital Management, LLC (5.02%) | 176,057 | 5.02% | 13G (passive) | Dec 31, 2025 |
| William Blank Joint filing with Squadron Capital Management LLC (6.50%), Matthew Sesterhenn (6.50%) and 1 more | 173,861 | 6.50% | 13G (passive) | Oct 21, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NXTC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 288,303 | 6.30% | $461.28K | +50,000 | 0.05% |
| Adage Capital Partners Gp, L.L.C. | 277,202 | 6.06% | $443.52K | New | 0.00% |
| Sofinnova Investments, Inc. | 222,654 | 4.86% | $356.25K | – | 0.02% |
| Renaissance Technologies LLC | 171,202 | 3.74% | $273.92K | +110,668 | 0.00% |
| Vanguard Capital Management LLC | 156,842 | 3.43% | $250.95K | −3,631 | 0.00% |
| Millennium Management LLC | 88,112 | 1.92% | $140.98K | New | 0.00% |
| Boothbay Fund Management, LLC | 84,687 | 1.85% | $135.50K | +15,070 | 0.00% |
| Squadron Capital Management LLC | 64,464 | 1.41% | $103.14K | −200,536 | 0.03% |
| Verdad Advisers, LP | 60,451 | 1.32% | $96.72K | +17,496 | 0.09% |
| Pfizer Inc | 44,347 | 0.97% | $72.97K | −109,007 | 0.04% |
| Affinity Asset Advisors, LLC | 41,960 | 0.92% | $67.14K | −199,866 | 0.00% |
| BlackRock, Inc. | 37,348 | 0.82% | $59.76K | +9,555 | 0.00% |
| Hrt Financial LP | 36,450 | 0.80% | $58.00K | New | 0.00% |
| Jane Street Group, LLC | 32,725 | 0.71% | $52.36K | New | 0.00% |
| Geode Capital Management, LLC | 29,905 | 0.65% | $47.86K | −1,187 | 0.00% |
| Cardiff Park Advisors, LLC | 21,833 | 0.48% | $34.93K | – | 0.00% |
| Acadian Asset Management LLC | 18,982 | 0.41% | $30.00K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 16,134 | 0.35% | $25.81K | +119 | 0.00% |
| Nomura Asset Management International Inc. | 12,500 | 0.27% | $20.00K | New | 0.00% |
| Virtu Financial LLC | 10,991 | 0.24% | $18.00K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 30 | 2M | 37.9% | 11 / 8 | 5 / 7 | 1M | 1M |
| Q1 2026 | 26 | 2M | 47.4% | 7 / 3 | 4 / 4 | 0M | 0M |
| Q4 2025 | 24 | 2M | 41.5% | 10 / 5 | 4 / 2 | 1M | 0M |
| Q3 2025 | 16 | 1M | 18.3% | 16 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
16 funds held NXTC in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NXTC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 123,276 | 2.69% | $197.24K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 33,566 | 0.73% | $53.71K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 16,250 | 0.36% | $100.75K | 0.00% | May 31, 2026 |
| Nomura Healthcare Fund | 12,500 | 0.27% | $20.00K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 9,851 | 0.22% | $15.76K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 3,997 | 0.09% | $24.78K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 3,634 | 0.08% | $22.53K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 3,000 | 0.07% | $4.80K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,047 | 0.04% | $12.69K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 741 | 0.02% | $1.19K | 0.00% | Jun 30, 2026 |
| Diversified Equity Alpha Master Portfolio | 689 | 0.02% | $1.10K | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 59 | 0.00% | $245 | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 22 | 0.00% | $91 | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Richman | President & CEO, Director | 385,869 | 8.43% | Feb 3, 2026 |
| Udayan Guha | Chief Medical Officer | – | – | Feb 3, 2026 |
| Kevin G. Shaw | Sr VP, General Counsel | – | – | Feb 3, 2026 |
| Sourav Kundu | Sr VP, Dev. & Mfg. | – | – | Feb 3, 2026 |
| Timothy Mayer | Chief Operating Officer | – | – | Feb 3, 2026 |
| Steven P. Cobourn | Chief Financial Officer | – | – | Feb 3, 2026 |
| Sol Langermann | Chief Scientific Officer | 37,342 | 0.82% | Feb 3, 2025 |
| Elaine V. Jones | Director | – | – | Jun 22, 2026 |
| Anne Elizabeth Borgman | Director | – | – | Jun 22, 2026 |
| Ellen Feigal | Director | – | – | Jun 22, 2026 |
| Stephen W. Webster | Director | – | – | Jun 22, 2026 |
| John G. Houston | Director | – | – | Jun 22, 2026 |
| David S. Kabakoff | Director | 62,237 | 1.36% | Jun 22, 2026 |
| Daniel Schneeberger | 10% owner | – | – | Nov 13, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | 750,289 | 16.39% | Nov 13, 2026 |
| Renhong Tang | – | – | – | Aug 12, 2026 |
| Pharmaceutical Group Ltd Simcere | – | – | – | Aug 12, 2026 |
| Jinsheng Ren | – | 338,636 | 7.40% | Aug 12, 2026 |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | – | 308,636 | 6.74% | Aug 12, 2026 |
| Simcere Zaiming, Inc. | – | 338,636 | 7.40% | Aug 12, 2026 |
| Simcere Zaiming Pharmaceutical Co., Ltd. | – | – | – | Aug 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC 10% owner | Nov 11, 2026 | Buy | +12,333 | $5.10 | $62.90K | 750,289 |
| ADAR1 Capital Management, LLC 10% owner | Nov 6, 2026 | Buy | +3,662 | $5.10 | $18.68K | 737,956 |
| ADAR1 Capital Management, LLC 10% owner | Nov 5, 2026 | Buy | +1,024 | $5.10 | $5.22K | 734,294 |
| ADAR1 Capital Management, LLC 10% owner | Oct 27, 2026 | Buy | +3,553 | $5.10 | $18.10K | 733,270 |
| ADAR1 Capital Management, LLC 10% owner | Oct 26, 2026 | Buy | +1,672 | $5.03 | $8.42K | 729,717 |
| ADAR1 Capital Management, LLC 10% owner | Oct 23, 2026 | Buy | +5,626 | $4.83 | $27.17K | 728,045 |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. – | Aug 10, 2026 | Sale | −30,000 | $6.16 | $184.80K | 308,636 |
| ADAR1 Capital Management, LLC 10% owner | Jul 31, 2026 | Buy | +25,000 | $4.98 | $124.50K | 714,416 |
| ADAR1 Capital Management, LLC 10% owner | Jul 31, 2026 | Buy | +3,300 | $4.98 | $16.43K | 689,416 |
| ADAR1 Capital Management, LLC 10% owner | Jul 31, 2026 | Buy | +8,003 | $4.80 | $38.41K | 722,419 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +100,000 | $4.90 | $490.00K | 608,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +77,850 | $4.96 | $386.14K | 686,116 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +25,000 | $4.81 | $120.25K | 508,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +20,000 | $5.00 | $100.00K | 483,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +20,000 | $5.00 | $100.00K | 463,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +50,000 | $4.97 | $248.50K | 443,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 29, 2026 | Buy | +1,600 | $5.00 | $8.00K | 393,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 29, 2026 | Buy | +1,810 | $5.00 | $9.05K | 391,666 |
| ADAR1 Capital Management, LLC 10% owner | Jul 28, 2026 | Buy | +6,400 | $4.95 | $31.68K | 389,856 |
| ADAR1 Capital Management, LLC 10% owner | Jul 27, 2026 | Buy | +7,798 | $5.00 | $38.99K | 383,456 |
| Kevin N. Heller Chief Medical Officer | Jul 14, 2020 | Option exercise | +27,229 | $1.77 | $48.20K | 49,011 |
| Linda Liu SVP, Research | Nov 27, 2019 | Option exercise | +20,745 | $1.21 | $25.10K | 55,234 |
| Linda Liu SVP, Research | Nov 27, 2019 | Option exercise | +34,489 | $0.48 | $16.55K | 34,489 |
| Sofinnova Venture Partners IX, L.P. 10% owner | Nov 15, 2019 | Buy | +150,000 | $36.75 | $5.51M | 2,671,856 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +464,599 | – | – | 743,358 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +908,785 | – | – | 1,652,143 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +469,713 | – | – | 2,121,856 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +278,759 | – | – | 278,759 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Buy | +400,000 | $15.00 | $6.00M | 2,521,856 |
| Stella Xu Director | May 13, 2019 | Buy | +125,000 | $15.00 | $1.88M | 1,103,570 |
| Stella Xu Director | May 13, 2019 | Conversion | +978,570 | – | – | 978,570 |
| Timothy M. Shannon Director | May 13, 2019 | Buy | +50,000 | $15.00 | $750.00K | 2,254,442 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +285,867 | – | – | 2,204,442 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Buy | +350,000 | $15.00 | $5.25M | 2,711,013 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +442,438 | – | – | 2,361,013 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| Alexandria Venture Investments, LLC 10% owner | May 13, 2019 | Conversion | +197,993 | – | – | 197,993 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +442,438 | – | – | 2,361,013 |
| Chau Quang Khuong Director | May 13, 2019 | Buy | +350,000 | $15.00 | $5.25M | 2,711,013 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +285,867 | – | – | 2,204,442 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Buy | +50,000 | $15.00 | $750.00K | 2,254,442 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NextCure's stock actually held short. Settlement fails (shares not delivered on time) peaked at 37,037 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?